Cathepsin G cleaves and activates IL-36γ and promotes the inflammation of psoriasis.

Background: IL-36 gamma is considered to be a valuable biomarker in psoriatic patients, which is expressed as an inactive precursor that needs to be proteolytically processed and activated, and neutrophil-derived proteases seemed to be potent activating enzymes of IL-36 gamma. Objectives: This study aims to investigate the activation of IL-36 gamma by cathepsin G (CG) and neutrophil elastase (NE). Materials and methods: We used inactive recombinant full-length (FL)-IL-36 gamma with different doses of NE or CG to stimulate HaCaT cells; neutrophil extracellular traps (NETs) were prepared to act on FL-IL-36 gamma and then stimulate HaCaT cells. Real-time quantitative PCR and ELISA were performed to detect CXCL-1 and CXCL-8 expression. We developed imiquimod-induced psoriasis-like mouse model to evaluate the effect of hypodermic injection of neutrophil-derived protease or its inhibitor. Histopathology and Western blotting were conducted for effect assessment. Results: Purified CG cleaved and activated recombinant human FL-IL-36 gamma to promote CXCL-1 and CXC L-8 expression by human keratinocytes, and NETs activated FL-IL-36 gamma and the activation was inhibited by serpin A3. CG induced expression of a more truncated IL-36 gamma in psoriasiform lesion of mice and aggravated the psoriasis-like lesion induced by imiquimod, whereas recombinant serpin A3 alleviated the severity of the psoriasis-like mouse mode. Conclusion: CG has the ability to cleave and activate IL-36 gamma and aggravate imiquimod-induced mouse psoriasilbrm lesion. Thus, CG-specific inhibitors might be promising therapeutic drugs for psoriasis.